18F-sodium fluoride positron emission tomography-computed tomography may better detect skeletal metastases in patients Further study is needed to determine if certain biomarkers can aid in determining effectiveness and safety. Two studies emphasize the need for ethnically diverse prostate cancer genomics data and accessible genetic testing. An analysis of enrollment incidence ratios revealed that Black & Hispanic patients were both underrepresented in U.S. trials. There was an improvement in freedom from PSA progression among patients assigned to enzalutamide compared with placebo. The effectiveness of PSMA PET was compared with conventional imaging & liver biopsy, and a radiomic model was also evaluated. Between [225Ac]Ac-SibuDAB and [225Ac]Ac-PSMA-617, one treatment was more effective against PSMA-positive tumor xenografts. 68Ga-PSMA PET/CT may play a role in the detection of local or systemic disease in patients with prostate cancer. The history of robot-assisted laparoscopic & open radical prostatectomies are discussed with their outcomes and future uses. Dr. Catherine H. Marshall is interviewed on the use and future of chemotherapy for the treatment of advanced prostate cancer. A polygenic hazard score (PHS290) is able to stratify US veterans of diverse ancestry for lifetime risk of prostate cancer. A study assessed the link between benign prostatic hyperplasia (BPH) and prostate cancer (PCa). A corrected genetic risk score (GRS) based on non-European racial/ethnic populations is more appropriate for genetic testing. Genetic testing rates are low for prostate cancer. Olaparib is the first and only PARP inhibitor to be approved for use in the EU for the treatment of prostate cancer patients. Andrew Armstrong, MD ScM FACP, is interviewed by Daniel Tennenbaum, MD on new research in phenotypic precision medicine. Using the MRI and combined biopsy strategy resulted in an incremental cost-effectiveness ratio of $53,736. Improvements in PET–CT and repeat issues with ⁹⁹mTc supply have sparked interest in ¹⁸F-NaF PET–CT to detect bone ... The phase 2 TheraP trial found that higher gallium-68–labeled PSMA-11-PET SUVmean had a higher chance of PSA response. A radiotracer for prostate cancer biopsy punching can be applied to targeted biopsy to reduce the need for saturated biopsy.